Microsoft word - acne laminate.doc

Suggestions for treatment
Treatment Options1
Acne Severity
Mild to moderate

2nd line options
• Topical retinoid + BP2 • Topical antibiotic3,4 + BP • Topical antibiotic3,4 + Moderate to severe
3rd line options
*Severe presentations (e.g. nodulocystic acne or acne fulminans) may require initiation of therapy with 3rd line
Combined oral contraceptives

Spironolactone or low dose6,8
oral isotretinoin
1 – Wait 8 to 12 weeks before changing from one therapy to another. 2 – It is reasonable to consider topical retinoids with BP as second line therapy, especially if the goal is to minimize antibiotic use. Evidence for the effect of benzoyl peroxide plus a topical retinoid versus either agent alone is inconsistent. (There is consistent evidence that topical clindamycin + BP is superior to BP alone). 3 – Do not switch from one topical antibiotic to another. Change to oral agent if antibiotic treatment desired
4 – Long term therapy with topical or oral antibiotics is not recommended due to concerns of developing
resistance. • Topical or oral antibiotics are used only to gain a measure of control over inflammatory lesions and should be stopped when there is no further inflammation.
• Response to topical or oral antibiotics usually occurs within 3 months. Once patients respond (no further inflammation) consider “stepping down” to benzoyl peroxide or a topical retinoid to maintain
response.
5 – The addition of benzoyl peroxide may address resistance concerns and may lead to better outcomes. Separate the application of benzoyl peroxide products from other topical products by applying one in the morning and the other in the evening. 6 – When starting oral isotretinoin discontinue other therapies. 7 – 1st line in women also wanting birth control or add on treatment to 1st and 2nd line therapies in women
with no contraindications. Some suggest use ahead of oral antibiotics. 8 – Expert opinion suggests 20 mg oral isotretinoin daily X 6 months as treatment option for adult onset acne. Wholesale costs of acne therapies, not including dispensing fee - June 2008
Preparations
Concentration
Pack size
Cost / g or ml
Benzoyl Peroxide
Water based gel

Alcohol based gel
Acetone based gel
Retinoids
Cream

Solution
1 - costs of different concentrations are the same for each preparation Combination BP/topical antibiotic preparations
Clindoxyl (BP 5%/Clin 1%) is given a 4 month expiry date after dispensing.
Stored at room temperature by the patient.
BenzaClin (BP 5%/Clin 1%) is given a 3 month expiry date after dispensing.
Stored at room temperature by the patient.

Benzamymcin (BP 5%/Ery 3%) is given a 3 month expiry date after dispensing.
Requires refrigeration by the patient.
Topical antibiotics
Preparations

Concentration
Pack size
Cost / g or ml
Clindamycin
Erythromycin
Combination products
BP + clindamycin

BP + erythro
Tretinoin + erythro
Oral antibiotics

Strength
Cost / unit
90 day cost
Tetracyclines
Erythromycins
Combined oral contraceptives
Trade name

Contents
Cost / month
Oral isotretinoin
Cost: 5 mos for
Trade name
60 kg person
Then alternate 40 mg on day 1 and 80 mg on day 2 for 4 months 40 mg once daily for 1 month Then 60 mg once daily (40 mg plus 2 x 10 mg) for 4 months 40 mg once daily for 1 month Then alternate 40 mg on day 1 and 80 mg on day 2 for 4 months 40 mg once daily for 1 month Then 60 mg once daily (40 mg plus 2 x 10 mg) for 4 months Dalhousie Academic Detailing Service. Source McKesson Canada Maritimes, Wholesale Distributor. June 2008

Source: http://cme.medicine.dal.ca/files/Acne_Tx_costs.pdf

Integrerad tro final

integrerad BÖRJAN - Mark 16:15 Gå ut i hela världen och predika de goda nyheterna för alla människor VI ÄR HÄR! SLUTET- Upp 7:9 en stor skara som ingen kunde räkna, alla folkslag och stammar och William Carey 1761-1831 länder och språk Pioneer Tentmaker Missionary to India 97% av onådda bor i länder där traditionell misssio

4099fnl.pdf

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) December 2000 Additional copies are available from: Office of Training and Communications Division of Communications Management (Internet) http://www.fda.gov/cder/guidance/index.htm Office of Communication

Copyright © 2011-2018 Health Abstracts